홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
PDSB
#3617
PDS Biotechnology Corporation Common Stock
0.6
8
-1.45%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-1.45%
월간 변동
-32.00%
6달 변화
-47.29%
년간 변동율
-52.45%
이전 종가
0.6
9
Open
0.6
8
Bid
Ask
Low
0.6
8
High
0.6
8
양
6
마켓
주식
헬스케어
PDSB
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.26 M
28.45 M
30.72 M
36.68 M
45.4 M
—
Valuation ratios
Enterprise value
18.8 M
165.23 M
252.48 M
132.3 M
32.3 M
100.08 M
Price to earnings ratio
—
-12.27
-7.43
-3.71
-1.58
-5.53
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
-16.61
-11.81
-4.74
-1.7
-5.85
Price to book ratio
—
3.28
6.9
6.1
3.13
4.88
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.48
-0.25
-0.53
-0.72
-0.83
-0.85
Return on equity %
0.55
-0.27
-0.93
-1.64
-1.98
-2.34
Return on invested capital %
9 999.18
-16.09 K
-23.94 K
-6 611.39
-1 706.76
-966.63
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.28
17.8
7.79
4.33
2.64
9.97
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0.3
0.33
0.2
1
Long term debt to total equity ratio
—
—
0.52
0.75
0.48
2.84
Per share metrics
Operating cash flow per share
—
-0.49
-0.9
-1.09
-0.96
-0.77
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
2.55
2.58
1.83
1.14
3.39
Net current asset value per share
—
2.61
2.67
1.91
1.24
3.61
Tangible book value per share
—
2.47
1.54
0.84
0.52
1.62
Working capital per share
—
2.46
2.33
1.47
0.77
2.16
Book value per share
—
2.47
1.54
0.84
0.52
1.62
뉴스
PDS 바이오텍, 3상 시험 변경… 신속 승인 경로 추가
PDS Biotech amends Phase 3 trial to add accelerated approval path
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study
PDS 바이오, 암 면역치료제 PDS0101 특허 확보
PDS Biotech secures patent for cancer immunotherapy PDS0101
PDS Biotech, FDA 회의 후 주가 급등: 승인 가속화 기대
PDS Biotech stock soars after FDA meeting provides accelerated approval path
PDS 바이오텍, 3상 암 임상시험 수정안 제출
PDS Biotech submits amended protocol for phase 3 cancer trial
PDS Biotech secures new patent for cancer immunotherapy in Japan
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
PDS Biotech, FDA와 신속 승인 논의